Ross\Johnson & Associates’s CME Group CME Stock Holding History

Ross\Johnson & Associates’s Portfolio CME Stock Details CME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30	Closed	-$7.96K	–	233
2025 Q1	$7.96K	Buy	+30	New	+$7.4K	0.14%	63

Other funds holding CME

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ross\Johnson & Associates's CME Position: Q2 2025 in Review

Ross\Johnson & Associates sold out of CME Group (CME) in Q2 2025, closing a stake of 30 shares — an estimated $7.96K sold.

Ross\Johnson & Associates first reported a position in CME in Q1 2025 and held it in 1 quarter. The position peaked at $7.96K in Q1 2025. 1,660 funds tracked by Wall St. Rank hold CME as of Q2 2025.

Ross\Johnson & Associates reported no remaining CME Group position as of Q2 2025 after selling out during the quarter.
Ross\Johnson & Associates sold 30 CME Group shares in Q2 2025, an estimated $7.96K.
Ross\Johnson & Associates first reported a position in CME Group in Q1 2025 and held it in 1 quarter.
Ross\Johnson & Associates's CME Group position peaked at $7.96K in Q1 2025.
1,660 funds tracked by Wall St. Rank held CME Group as of Q2 2025.

Based on Ross\Johnson & Associates's 13F filing for Q2 2025, filed 15 Aug 2025.